Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Immuno-radiotherapy: rationale and new perspectives for breast cancer patients

BGICC 2023

19 - 20 Jan 2023

Published: 31 Jan 2023

Views: 12

Rating:

Save

Prof Roberto Orecchia - University of Milan, Milan, Italy

Prof Roberto Orecchia speaks to ecancer about his talk on the use of immuno-radiotherapy for breast cancer patients.

He begins his talk by explaining immunotherapy plays a vital role in the management of a large number of solid tumours.

He continues by exploring different combinations with other cancer treatments and the positive outcome if explored further.

Related Videos

Choosing cancer medicines wisely in Africa

Dr Harrison Chuwa - Aga Khan Hospital, Dar es Salaam, Tanzania

Choosing cancer medicines wisely in Africa ( Dr Harrison Chuwa - Aga Khan Hospital, Dar es Salaam, Tanzania )

Advancing breast cancer diagnosis in the developing world

Dr Hans Junkermann, Prof Dr.Erkin Arıbal and Dr Richard Rainsbury

Advancing breast cancer diagnosis in the developing world ( Dr Hans Junkermann, Prof Dr.Erkin Arıbal and Dr Richard Rainsbury )

Multiple myeloma

Dr Bishesh Poudyal - Civil Service Hospital, Kathmandu, Nepal

Multiple myeloma ( Dr Bishesh Poudyal - Civil Service Hospital, Kathmandu, Nepal )

Erdafitinib demonstrates efficacy in intermediate-risk non–muscle-invasive...

Prof Siamak Daneshmand - University of Southern California, Los Angeles, USA

Erdafitinib demonstrates efficacy in intermediate-risk non–muscle-invasive bladder cancer with FGFR alterations ( Prof Siamak Daneshmand - University of Southern California, Los Angeles, USA )

Updates on HER2-low breast cancer

Prof Sana Al Sukhun - University of Jordan, Amman, Jordan

Updates on HER2-low breast cancer ( Prof Sana Al Sukhun - University of Jordan, Amman, Jordan )

Novel antibody-drug conjugates (ADCs) technologies for management of mBC

Prof Hope Rugo - University of California San Francisco, San Francisco, USA

Novel antibody-drug conjugates (ADCs) technologies for management of mBC ( Prof Hope Rugo - University of California San Francisco, San Francisco, USA )

Survival outcomes in randomised controlled trials with first-line CDK4/6i in...

Prof Matti Aapro - Genolier Cancer Centre, Genolier, Switzerland

Survival outcomes in randomised controlled trials with first-line CDK4/6i in HR+/HER2-Ve breast cancer ( Prof Matti Aapro - Genolier Cancer Centre, Genolier, Switzerland )

Comment: Artificial Intelligence and surgical management of Axilla

Prof Mehra Golshan - Yale School of Medicine, New Haven, USA

Comment: Artificial Intelligence and surgical management of Axilla ( Prof Mehra Golshan - Yale School of Medicine, New Haven, USA )

HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan

Prof Naoto Ueno - The University of Texas MD Anderson Cancer Center, Houston...

HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan ( Prof Naoto Ueno - The University of Texas MD Anderson Cancer Center, Houston, USA )

More from ecancer